Summaries for Patients |

Cost-Effectiveness of Screening for Microsatellite Instability To Detect Hereditary Nonpolyposis Colorectal Cancer FREE

[+] Article, Author, and Disclosure Information

Copyright ©2004 by the American College of Physicians

The summary below is from the full report titled “Cost-Effectiveness of Microsatellite Instability Screening as a Method for Detecting Hereditary Nonpolyposis Colorectal Cancer.” It is in the 16 October 2001 issue of Annals of Internal Medicine (volume 135, pages 577-588). The authors are SD Ramsey, L Clarke, R Etzioni, M Higashi, K Berry, and N Urban.

Ann Intern Med. 2001;135(8_Part_1):S48. doi:10.7326/0003-4819-135-8_Part_1-200110160-00004
Text Size: A A A

What is the problem and what is known about it so far?

Colorectal cancer is cancer of the colon (large intestine) or rectum. Some colorectal cancer is caused by an inherited cancer syndrome called hereditary nonpolyposis colorectal cancer (HNPCC). People in families with HNPCC have a higher than usual risk for colorectal and some other cancers. Genetic testing to detect a predisposition for hereditary colorectal cancer is now possible, but testing for the gene abnormalities (mutations) associated with HNPCC is too expensive to be done on all patients with colorectal cancer. Consequently, the National Cancer Institute (NCI) has published guidelines for looking for HNPCC in patients with new diagnoses of colorectal cancer. The guidelines advise testing only patients who meet clinical criteria that suggest a high risk for HNPCC (for example, one or more first-degree relatives with colorectal cancer or one of the other HNPCC-associated cancers, or young age at diagnosis) and whose tumors also show an abnormality in the DNA known as microsatellite instability. Most olorectal tumors in HNPCC (85% to 90%) have microsatellite instability. However, many patients who have tumors that show microsatellite instability do not have HNPCC. The guidelines recommend doing further genetic testing for HNPCC in patients who meet the clinical criteria and also have microsatellite instability. The reason to look for HNPCC is to identify families that need close screening. The cost-effectiveness of this strategy is not known.

Why did the researchers do this particular study?

To calculate the cost-effectiveness of the NCI strategy for screening for HNPCC compared with standard care (not screening for HNPCC).

Who was studied?

The researchers did not study actual patients. Instead, they used computers to simulate what might happen to a group of “virtual” patients with new diagnoses of colorectal cancer.

How was the study done?

The researchers set up a computer model to simulate what would happen to patients with colorectal cancer and their siblings and children if screening for HNPCC was or was not done. They fed information from a variety of sources about the costs, benefits, and risks of screening into the computer model. They then calculated the cost per year of life saved due to early detection of HNPCC by the screening tests.

What did the researchers find?

When only the costs and benefits related to the patients with cancer were considered, screening for HNPCC cost $42 210 per year of life gained. When the costs and benefits that apply to the patients' siblings and children were also considered, the cost dropped to only $7557 per year of life gained. These cost-effectiveness estimates are within the range that U.S. society generally considers acceptable.

What were the limitations of the study?

Errors in the assumptions that went into the model could influence the results.

What are the implications of the study?

Looking for HNPCC in patients with new diagnoses of colorectal cancer seems to be an effective use of health care resources, especially if the benefits that relate to patients' siblings and children are considered.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.